Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/181208
Title: | Autoantibody screening in Guillain–Barré syndrome |
Author: | Lleixà, Cinta Martín Aguilar, Lorena Pascual Goñi, Elba Franco, Teresa Caballero, Marta Luna, Noemí de Gallardo, Eduard Suárez Calvet, Xavier Martínez Martínez, Laura Diaz Manera, Jordi Rojas García, Ricard Cortés Vicente, Elena Turón, Joana Casasnovas Pons, Carlos Homedes, Christian Gutiérrez Gutiérrez, Gerardo Jimeno Montero, María Concepción Berciano, José Sedano-tous, Maria José García Sobrino, Tania Pardo Fernández, Julio Márquez Infante, Celedonio Rojas Marcos, Iñigo Jericó Pascual, Ivonne Martínez Hernández, Eugenia Morís de la Tassa, Germán Domínguez González, Cristina Juárez, Cándido Illa Sendra, Isabel Querol, Luis |
Keywords: | Immunoglobulines Malalties del sistema nerviós Immunoglobulins Nervous system Diseases |
Issue Date: | 1-Nov-2021 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | Background: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain-Barré syndrome. Methods: Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed. Results: None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors. Conclusion: Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies targeting nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic value; (3) further antigen-discovery experiments may elucidate other potential antigens in GBS. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s12974-021-02301-0 |
It is part of: | Journal of Neuroinflammation, 2021, vol. 18, num. 1 |
URI: | http://hdl.handle.net/2445/181208 |
Related resource: | https://doi.org/10.1186/s12974-021-02301-0 |
ISSN: | 1742-2094 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s12974-021-02301-0.pdf | 1.98 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License